Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ollin Biosciences, Inc.
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Two Different Formulations of Intravitreal OLN324 in Adult Participants With Either Neovascular (Wet) Age-related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Be willing and able to understand the study procedures and the risks involved and provide written informed consent before the first study-related activity
DME patients must be ≥ 18 years of age, nAMD patients must be ≥ 50 years of age
Diagnosis of either DME or nAMD. nAMD patients must be treatment naïve. DME patients can be either treatment naïve or treatment experienced
DME patients must have best corrected visual acuity of 78 to 25 letters
nAMD patients must have best corrected visual acuity of 80 to 25 letters
You may not be if
If pregnant or breastfeeding
History of cataract surgery and/or Yttrium-Aluminum Garnet (YAG) for removal of posterior capsular opacification (PCO) within 90 days
